Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2012 Jul 1;10(7):821-9.
doi: 10.6004/jnccn.2012.0086.

Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines

Robert W Carlson  1 , D Craig Allred, Benjamin O Anderson, Harold J Burstein, Stephen B Edge, William B Farrar, Andres Forero, Sharon Hermes Giordano, Lori J Goldstein, William J Gradishar, Daniel F Hayes, Clifford A Hudis, Steven Jay Isakoff, Britt-Marie E Ljung, David A Mankoff, P Kelly Marcom, Ingrid A Mayer, Beryl McCormick, Lori J Pierce, Elizabeth C Reed, Mary Lou Smith, Hatem Soliman, George Somlo, Richard L Theriault, John H Ward, Antonio C Wolff, Richard Zellars, Rashmi Kumar, Dorothy A Shead; National Comprehensive Cancer Network
Affiliations
Practice Guideline

Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines

Robert W Carlson et al. J Natl Compr Canc Netw. .

Abstract

These NCCN Guidelines Insights highlight the important updates/changes specific to the management of metastatic breast cancer in the 2012 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer. These changes/updates include the issue of retesting of biomarkers (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2) on recurrent disease, new information regarding first-line combination endocrine therapy for metastatic disease, a new section on monitoring of patients with metastatic disease, and new information on endocrine therapy combined with an mTOR inhibitor as a subsequent therapeutic option.

PubMed Disclaimer

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29. - PubMed
    1. Allred DC, Carlson RW, Berry DA, et al. NCCN Task Force Report: estrogen receptor and progesterone receptor testing in breast bancer by immunohistochemistry. J Natl Compr Canc Netw. 2009;7(Suppl 6):S1–21. - PubMed
    1. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–2795. - PMC - PubMed
    1. Carlson RW, Moench SJ, Hammond ME, et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006;4(Suppl 3):S1–22. - PubMed
    1. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–145. - PubMed

Publication types

MeSH terms

Substances